IL-17 and infections
IL-17 e infecciones
Read
6531
Timeswas read the article
2839
Total PDF
3692
Total HTML
Share statistics
array:22 [ "pii" => "S000173101470016X" "issn" => "00017310" "doi" => "10.1016/S0001-7310(14)70016-X" "estado" => "S300" "fechaPublicacion" => "2014-10-01" "aid" => "70016" "copyright" => "Academia Española de Dermatología y Venereología" "copyrightAnyo" => "2014" "documento" => "article" "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2014;105 Supl 1:34-40" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 928 "formatos" => array:3 [ "EPUB" => 33 "HTML" => 293 "PDF" => 602 ] ] "itemSiguiente" => array:17 [ "pii" => "S0001731014700171" "issn" => "00017310" "doi" => "10.1016/S0001-7310(14)70017-1" "estado" => "S300" "fechaPublicacion" => "2014-10-01" "aid" => "70017" "copyright" => "Academia Española de Dermatología y Venereología" "documento" => "article" "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2014;105 Supl 1:41-50" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 891 "formatos" => array:3 [ "EPUB" => 39 "HTML" => 229 "PDF" => 623 ] ] "en" => array:10 [ "idiomaDefecto" => true "titulo" => "Role of IL-17 and IL-22 in autoimmunity and cancer" "tienePdf" => "en" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "41" "paginaFinal" => "50" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Papel de la IL-17 e IL-22 en autoinmunidad y cáncer" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "S.J. Blake, M.W.L. Teng" "autores" => array:2 [ 0 => array:2 [ "nombre" => "S.J." "apellidos" => "Blake" ] 1 => array:2 [ "nombre" => "M.W.L." "apellidos" => "Teng" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731014700171?idApp=UINPBA000044" "url" => "/00017310/00000105000000S1/v1_201411120051/S0001731014700171/v1_201411120051/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "S0001731014700158" "issn" => "00017310" "doi" => "10.1016/S0001-7310(14)70015-8" "estado" => "S300" "fechaPublicacion" => "2014-10-01" "aid" => "70015" "copyright" => "Academia Española de Dermatología y Venereología" "documento" => "article" "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2014;105 Supl 1:21-33" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 770 "formatos" => array:3 [ "EPUB" => 32 "HTML" => 273 "PDF" => 465 ] ] "en" => array:10 [ "idiomaDefecto" => true "titulo" => "IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease" "tienePdf" => "en" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "21" "paginaFinal" => "33" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "IL-17 e IL-17R: una diana terapéutica favorable para la enfermedad psoriásica" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Mitra, S.K. Raychaudhuri, S.P. Raychaudhuri" "autores" => array:3 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Mitra" ] 1 => array:2 [ "nombre" => "S.K." "apellidos" => "Raychaudhuri" ] 2 => array:2 [ "nombre" => "S.P." "apellidos" => "Raychaudhuri" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731014700158?idApp=UINPBA000044" "url" => "/00017310/00000105000000S1/v1_201411120051/S0001731014700158/v1_201411120051/en/main.assets" ] "en" => array:11 [ "idiomaDefecto" => true "titulo" => "IL-17 and infections" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "34" "paginaFinal" => "40" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Y. Ling, A. Puel" "autores" => array:2 [ 0 => array:3 [ "nombre" => "Y." "apellidos" => "Ling" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 1 => array:4 [ "nombre" => "A." "apellidos" => "Puel" "email" => array:1 [ 0 => "anne.puel@inserm.fr" ] "referencia" => array:4 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 3 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM 1163, Paris, France" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Imagine Institute, University Paris Descartes, Paris, France" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, the Rockefeller University, New York, NY, USA" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "*" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "IL-17 e infecciones" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec360874" "palabras" => array:4 [ 0 => "IL-17" 1 => "Primary immunodeficiencies" 2 => "Chronic mucocutaneous candidiasis" 3 => "Inborn errors of IL-17 immunity" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec360875" "palabras" => array:4 [ 0 => "IL-17" 1 => "Inmunodeficiencias primarias" 2 => "Candidiasis mucocutánea crónica" 3 => "Errores innatos de la inmunidad IL-17" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">IL-17 immunity has been shown to be essential for mucocutaneous protection against <span class="elsevierStyleItalic">Candida albicans</span> in mice and humans. However, mice with defective IL-17 immunity display broader susceptibility, as they are also prone to infections with diverse infectious agents at various sites. Humans with genetic defects affecting their IL-17 immunity usually suffer from chronic mucocutaneous candidiasis (CMC): recurrent or persistent infections of the skin, nails, and mucosae with <span class="elsevierStyleItalic">C. albicans</span>, with or without other clinical signs. Most patients with autosomal dominant (AD) hyper-IgE syndrome (HIES) due to STAT3 deficiency or AD STAT1 gain-of-function display impaired IL-17-producing T-cell development, and CMC is one of their principal clinical manifestations. Similarly, patients with autosomal recessive (AR) autoimmune polyendocrine syndrome type 1 (APS-1) caused by AIRE deficiency have high levels of neutralizing autoantibodies against IL-17A, IL-17F and/or IL-22 and present CMC as their only infectious disease. Finally, CMC is the main clinical phenotype observed in patients with inborn errors specifically affecting IL-17 immunity. Indeed, patients with AD IL-17F deficiency or AR IL-17RA or ACT1 deficiency display CMC and, to a lesser extent, superficial staphylococcal diseases. <span class="elsevierStyleItalic">Candida</span> infection was recently reported in psoriasis patients treated with anti-IL-17A antibodies. Careful monitoring for CMC is thus important during anti-IL-17 treatment.</p>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Se ha demostrado que la inmunidad IL-17 es esencial para la protección mucocutánea contra la <span class="elsevierStyleItalic">Candida albicans</span> en ratones y humanos. Independientemente, los ratones con inmunidad IL-17 defectuosa muestran una susceptibilidad más amplia, de modo que también son propensos a infecciones por diversos agentes infecciosos en varios lugares. Los humanos con defectos genéticos que afectan su inmunidad IL-17 habitualmente padecen candidiasis mucocutánea crónica (CMC): infecciones cutáneas recurrentes o persistentes de uñas y mucosas por <span class="elsevierStyleItalic">C. albicans</span>, con o sin otros signos clínicos. Muchos pacientes con síndrome de hiper IgE autosómico dominante (AD-HIES) debido a deficiencia STAT3 o a aumento de función AD STAT1 muestran un desarrollo dañado de células T productoras de IL-17 y la CMC es una de sus principales manifestaciones. De igual manera, los pacientes con síndrome poliendocrino autoinmune tipo 1 recesivo autosómico (AR-APS-1) causado por deficiencia de AIRE (regulador autoinmune) presentan altos niveles de anticuerpos neutralizantes contra IL-17A, IL-17F y/o IL-22 y padecen CMC como su única enfermedad infecciosa. Finalmente, la CMC es el principal fenotipo clínico observado en pacientes con errores innatos, específicamente aquellos que afectan la inmunidad IL-17. De hecho, los pacientes con deficiencia AD IL-17F o deficiencia IL-17RA o ACT1 presentan CMC y, en menor medida, enfermedades estafilocócicas superficiales. Se ha informado recientemente CMC en pacientes tratados con anticuerpos anti-IL-17A. Es importante el control cuidadoso de la CMC en estos pacientes durante el tratamiento con anti-IL-17A.</p>" ] ] ] "idiomaDefecto" => "en" "url" => "/00017310/00000105000000S1/v1_201411120051/S000173101470016X/v1_201411120051/en/main.assets" "Apartado" => array:4 [ "identificador" => "6148" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/00017310/00000105000000S1/v1_201411120051/S000173101470016X/v1_201411120051/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S000173101470016X?idApp=UINPBA000044" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 4 | 13 | 17 |
| 2024 October | 29 | 66 | 95 |
| 2024 September | 26 | 36 | 62 |
| 2024 August | 50 | 69 | 119 |
| 2024 July | 29 | 32 | 61 |
| 2024 June | 66 | 46 | 112 |
| 2024 May | 39 | 51 | 90 |
| 2024 April | 37 | 37 | 74 |
| 2024 March | 37 | 28 | 65 |
| 2024 February | 28 | 65 | 93 |
| 2024 January | 29 | 47 | 76 |
| 2023 December | 27 | 16 | 43 |
| 2023 November | 35 | 37 | 72 |
| 2023 October | 53 | 19 | 72 |
| 2023 September | 41 | 32 | 73 |
| 2023 August | 22 | 21 | 43 |
| 2023 July | 36 | 38 | 74 |
| 2023 June | 20 | 25 | 45 |
| 2023 May | 36 | 32 | 68 |
| 2023 April | 28 | 37 | 65 |
| 2023 March | 38 | 42 | 80 |
| 2023 February | 49 | 35 | 84 |
| 2023 January | 25 | 29 | 54 |
| 2022 December | 30 | 43 | 73 |
| 2022 November | 33 | 27 | 60 |
| 2022 October | 26 | 22 | 48 |
| 2022 September | 21 | 39 | 60 |
| 2022 August | 29 | 34 | 63 |
| 2022 July | 28 | 31 | 59 |
| 2022 June | 19 | 27 | 46 |
| 2022 May | 26 | 36 | 62 |
| 2022 April | 26 | 42 | 68 |
| 2022 March | 35 | 57 | 92 |
| 2022 February | 33 | 36 | 69 |
| 2022 January | 25 | 51 | 76 |
| 2021 December | 20 | 52 | 72 |
| 2021 November | 25 | 61 | 86 |
| 2021 October | 25 | 63 | 88 |
| 2021 September | 34 | 70 | 104 |
| 2021 August | 16 | 48 | 64 |
| 2021 July | 28 | 44 | 72 |
| 2021 June | 33 | 42 | 75 |
| 2021 May | 22 | 73 | 95 |
| 2021 April | 28 | 107 | 135 |
| 2021 March | 32 | 47 | 79 |
| 2021 February | 27 | 28 | 55 |
| 2021 January | 15 | 33 | 48 |
| 2020 December | 18 | 31 | 49 |
| 2020 November | 25 | 37 | 62 |
| 2020 October | 13 | 21 | 34 |
| 2020 September | 15 | 17 | 32 |
| 2020 August | 18 | 28 | 46 |
| 2020 July | 11 | 24 | 35 |
| 2020 June | 61 | 29 | 90 |
| 2020 May | 1779 | 34 | 1813 |
| 2020 April | 17 | 33 | 50 |
| 2020 March | 21 | 15 | 36 |
| 2020 February | 1 | 2 | 3 |
| 2018 November | 0 | 2 | 2 |
| 2018 March | 2 | 1 | 3 |
| 2018 February | 21 | 20 | 41 |
| 2018 January | 15 | 18 | 33 |
| 2017 December | 31 | 25 | 56 |
| 2017 November | 11 | 23 | 34 |
| 2017 October | 7 | 19 | 26 |
| 2017 September | 6 | 20 | 26 |
| 2017 August | 9 | 21 | 30 |
| 2017 July | 13 | 15 | 28 |
| 2017 June | 20 | 35 | 55 |
| 2017 May | 16 | 27 | 43 |
| 2017 April | 21 | 34 | 55 |
| 2017 March | 23 | 23 | 46 |
| 2017 February | 8 | 30 | 38 |
| 2017 January | 14 | 25 | 39 |
| 2016 December | 13 | 16 | 29 |
| 2016 November | 25 | 24 | 49 |
| 2016 October | 28 | 40 | 68 |
| 2016 September | 0 | 1 | 1 |
| 2016 July | 1 | 3 | 4 |
| 2016 June | 0 | 7 | 7 |
| 2016 May | 0 | 14 | 14 |
| 2016 April | 0 | 11 | 11 |
| 2016 March | 0 | 13 | 13 |
| 2016 February | 0 | 14 | 14 |
| 2016 January | 0 | 12 | 12 |
| 2015 December | 0 | 14 | 14 |
| 2015 November | 0 | 19 | 19 |
| 2015 October | 0 | 14 | 14 |
| 2015 September | 0 | 17 | 17 |
| 2015 August | 0 | 10 | 10 |
| 2015 July | 0 | 1 | 1 |
| 2015 June | 0 | 6 | 6 |
| 2015 May | 0 | 3 | 3 |
| 2015 April | 0 | 12 | 12 |
| 2015 March | 0 | 11 | 11 |
| 2015 February | 7 | 1 | 8 |
| 2015 January | 0 | 1 | 1 |
| 2014 December | 1 | 0 | 1 |
| 2014 November | 1 | 0 | 1 |
Show all
